Technology ID
TAB-4938
Advancing Adenovirus Serotype 14 Vaccine Development: A Novel Approach
E-Numbers
E-133-2011-0
Lead Inventor
Gall, Jason
Lead IC
NIAID
Co-Inventors
Nabel, Gary
Kahl, Christoph
ICs
NIAID
Applications
Vaccines
Therapeutic Areas
Respiratory
Infectious Disease
Development Stages
Clinical Phase I
Research Products
Research Equipment
Plasmids/Vectors
Human Cell Lines
Computational models/software
Antibodies
Animal Models
The technology represents a groundbreaking approach to combatting adenovirus serotype 14 (Ad14) infections by employing a live attenuated Ad14 virus to induce a robust immune response in mammals. This method is designed to provide protection against severe infections and fatalities resulting from the emergence of Ad14 variants. Currently advancing through the Clinical Phase I stage of development, this innovative strategy holds significant promise in addressing a critical public health need for effective Ad14 vaccines.
Commercial Applications
The potential applications of this technology extend beyond Ad14 vaccine development. The use of live attenuated viruses to induce immune responses could also be applied to other adenovirus serotypes or even to other viral infections. Furthermore, the strategy of targeting specific emerging variants of a virus could be adapted for use in developing vaccines against other rapidly evolving viruses, addressing a broader range of infectious disease threats. Additionally, the success of this approach in inducing robust immune responses could have implications for the development of vaccines against other pathogens, potentially revolutionizing vaccine design and efficacy.
Competitive Advantages
This technology offers several key competitive advantages in the field of adenovirus serotype 14 (Ad14) vaccine development. Firstly, its focus on utilizing a live attenuated Ad14 virus sets it apart from traditional vaccine approaches, potentially leading to a more potent and durable immune response. Additionally, by targeting specific emerging variants of the Ad14 virus, this method addresses a critical public health need, providing a unique solution to combat these evolving threats. Furthermore, its advancement to the Clinical Phase I stage indicates promising progress towards clinical efficacy, positioning it as a frontrunner in the race to develop effective Ad14 vaccines.
Licensing Contact: